Semaglutide for metabolic dysfunction associated steatotic liver disease (MASH).
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
Semaglutide for metabolic dysfunction associated steatotic liver disease (MASH).
-
Narrated by:
-
By:
About this listen
Takeaways
- MASH is a significant obesity-related complication.
- Semaglutide shows promise in treating MASH.
- Weight loss is crucial for improving liver health.
- Bariatric surgery remains the most effective treatment.
- The Essence trial indicates a 63% resolution of NASH.
- New medications are being developed for obesity treatment.
- Early intervention is key to preventing severe liver damage.
- Accessibility of medications is a major concern.
- Comparative studies are essential for evaluating new treatments.
- Future treatments may include innovative delivery methods.
Chapters
00:00 Introduction to MASH and Semaglutide Study
04:29 Understanding Metabolic Dysfunction and Its Implications
08:02 Essence Trial: Semaglutide's Impact on MASH
12:58 Comparative Analysis of New Treatments for MASH
17:30 The Future of Obesity Treatment and Drug Accessibility
Join Vineyard - Dr. Spencer's online clinic
See the study
adbl_web_global_use_to_activate_T1_webcro805_stickypopup
No reviews yet